SCHEMBL2113288

SCHEMBL2113288

Nc1ccn(-c2ccccc2)c(=O)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.52
DDB1 Q16531 1/20 0.44
CRBN Q96SW2 1/20 0.44
TET2 Q6N021 1/20 0.41
TET1 Q8NFU7 1/20 0.41
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 1/20 0.40
HSD17B10 Q99714 1/20 0.40
XDH P47989 1/20 0.40
COMT P21964 1/20 0.40
LCK P06239 1/20 0.37
KIT P10721 1/20 0.37
SRC P12931 1/20 0.37
NOTUM Q6P988 1/20 0.37
MAPT P10636 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22468302 0.85 TET2 (0.60) SMN1; SMN2TET2TET1ALDH1A1COMT
SCHEMBL22421219 0.82 CYP2A6 (0.44) ALDH1A1HSD17B10MAPTGAA
SCHEMBL21508041 0.81 ALDH1A1 (0.35) SMN1; SMN2ALDH1A1MAPTATM
SCHEMBL22995728 0.81 XDH (0.42) SMN1; SMN2KDM4EALDH1A1HSD17B10XDH
SCHEMBL22522557 0.81 ALDH1A1 (0.46) SMN1; SMN2TET2TET1ALDH1A1HSD17B10
SCHEMBL22522218 0.81 XDH (0.46) SMN1; SMN2TET2TET1ALDH1A1HSD17B10
SCHEMBL30364487 0.80 FAAH (0.44) SMN1; SMN2TET2TET1ALDH1A1MAPT
SCHEMBL22234074 0.79 ALDH1A1 (0.45) SMN1; SMN2KDM4EALDH1A1XDHATM
SCHEMBL22386367 0.78 ALDH1A1 (0.42) SMN1; SMN2TET2TET1ALDH1A1LCK
SCHEMBL19867780 0.78 GAA (0.42) SMN1; SMN2KDM4EALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851456-B2 P2Y6 receptor agonists for treating lung diseases INSPIRE PHARMACEUTICALS, INC. (US) 2010-12-14 US claimed
EP-1895840-A2 P2Y6 RECEPTOR AGONISTS FOR TREATING LUNG DISEASES Inspire Pharmaceuticals, Inc. (US) 2008-03-12 EP claimed
US-20070015726-A1 P2Y6 receptor agonists for treating lung diseases MERCK SHARP & DOHME LLC 2007-01-18 US claimed
WO-2007002945-A2 P2Y6 RECEPTOR AGONISTS FOR TREATING LUNG DISEASES INSPIRE PHARMACEUTICALS, INC. (US) 2007-01-04 WO claimed
US-20230295119-A1 SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES GOSSAMER BIO SERVICES INC (US) 2023-09-21 US disclosed
US-20230295119-A1 SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES GOSSAMER BIO SERVICES INC (US) 2023-09-21 US disclosed
US-20230278987-A1 Antimicrobial Compounds and Methods CURZA GLOBAL, LLC. 2023-09-07 US disclosed
US-20230159491-A1 Antimicrobial Compounds and Methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-25 US disclosed
EP-4136073-A1 SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES Gossamer Bio Services, Inc. (US) 2023-02-22 EP disclosed
CN-115702145-A Substituted pyridines for the treatment of inflammatory diseases 戈萨默生物服务公司 2023-02-14 CN disclosed
WO-2021211741-A1 SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES GOSSAMER BIO SERVICES, INC. (US) 2021-10-21 WO disclosed
WO-2021211741-A1 SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES GOSSAMER BIO SERVICES, INC. (US) 2021-10-21 WO disclosed
US-20200316069-A1 CYTOSINE-BASED TET ENZYME INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-10-08 US disclosed
WO-2018048937-A1 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT Atea Pharmaceuticals, Inc. (US) 2018-03-15 WO disclosed
US-8158776-B2 P2Y6 receptor agonists for treating lung diseases INSPIRE PHARMACEUTICALS, INC. (US) 2012-04-17 US disclosed
US-20110054163-A1 P2Y6 RECEPTOR AGONISTS FOR TREATING LUNG DISEASES MERCK SHARP & DOHME LLC 2011-03-03 US disclosed
US-7851456-B2 P2Y6 receptor agonists for treating lung diseases INSPIRE PHARMACEUTICALS, INC. (US) 2010-12-14 US disclosed
EP-1895840-A2 P2Y6 RECEPTOR AGONISTS FOR TREATING LUNG DISEASES Inspire Pharmaceuticals, Inc. (US) 2008-03-12 EP disclosed
US-20070015726-A1 P2Y6 receptor agonists for treating lung diseases MERCK SHARP & DOHME LLC 2007-01-18 US disclosed
WO-2007002945-A2 P2Y6 RECEPTOR AGONISTS FOR TREATING LUNG DISEASES INSPIRE PHARMACEUTICALS, INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054163-A1 P2Y6 RECEPTOR AGONISTS FOR TREATING LUNG DISEASES P2RY6, P2RY1, P2RY11 SMN1; SMN2 3522/4885DDB1 3460/4885CRBN 4858/4885
US-20200316069-A1 CYTOSINE-BASED TET ENZYME INHIBITORS TET1, TET3, TET2 SMN1; SMN2 2787/4885DDB1 229/4885CRBN 718/4885
US-20230278987-A1 Antimicrobial Compounds and Methods CLPP, RPN2, MPO SMN1; SMN2 4805/4885DDB1 704/4885CRBN 4243/4885
US-20230295119-A1 SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES IRAK3, TYK2, IRAK2 SMN1; SMN2 2846/4885DDB1 3827/4885CRBN 1808/4885
US-20230159491-A1 Antimicrobial Compounds and Methods MPO, NISCH, RPN2 SMN1; SMN2 4817/4885DDB1 973/4885CRBN 4074/4885
US-20070015726-A1 P2Y6 receptor agonists for treating lung diseases P2RY6, P2RY1, P2RY11 SMN1; SMN2 3373/4885DDB1 3497/4885CRBN 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.